Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Emre Yekedüz
Advertisement
Dr. Emre Yekedüz is a medical oncologist and research fellow in medicine at Dana-Farber Cancer Institute in Boston.
Articles by Dr. Emre Yekedüz
A variant in the IL-7 gene may predict which patients with kidney cancer are more likely to experience side effects from immunotherapy.
Dr. Emre Yekedüz discusses his top 3 key takeaways from attending the 2025 ASCO Genitourinary (GU) Cancers Symposium.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Advertisement
Latest Updated Articles
What is on the Horizon for Kidney Cancer?Published: June 30th 2025 | Updated:
Gene Variant May Predict Side Effects From Kidney Cancer ImmunotherapyPublished: May 27th 2025 | Updated:
Advertisement
Advertisement
Trending on CURE
1
Targeted Therapies Are Transforming Lung Cancer Treatment
2
FDA Approves Epkinly Combo in Relapsed/Refractory Follicular Lymphoma
3
Inside the ‘Weird and Wacky’ Frontier of New Targeted Therapy for Lung Cancer
4
Understanding Emerging Cell Therapy in Lung Cancer
5
